82703-35-3

Basic information

• Product Name: 3,7-Dihydro-5,6-dimethyl-4H-pyrrolo[2,3-d]pyrimidin-4-one
• Synonyms: 3,7-Dihydro-5,6-dimethyl-4H-pyrrolo[2,3-d]pyrimidin-4-one;5,6-Dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4(3H)-one
• CAS NO: 82703-35-3
• Molecular Formula: C₈H₉N₃O
• Molecular Weight: 163
• Mol File: 82703-35-3.mol
• Article Data: 2

Chemical Properties

• Melting Point: 362℃
• Appearance: /
• Density: 1.43
• CAS DataBase Reference: 3,7-Dihydro-5,6-dimethyl-4H-pyrrolo[2,3-d]pyrimidin-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3,7-Dihydro-5,6-dimethyl-4H-pyrrolo[2,3-d]pyrimidin-4-one(82703-35-3)
• EPA Substance Registry System: 3,7-Dihydro-5,6-dimethyl-4H-pyrrolo[2,3-d]pyrimidin-4-one(82703-35-3)

Safety Data

• Hazardous Substances Data: 82703-35-3(Hazardous Substances Data)

Upstream product

• 103026-49-9 7-Cyclopentyl-5,6-dimethyl-7H-pyrrolo<2,3-d>pyrimidin-4(3H)-on 
• 103026-47-7 7-Cyclohexyl-5,6-dimethyl-7H-pyrrolo<2,3-d>pyrimidin-4(3H)-on 
• 103026-13-7 7-(2-Furanylmethyl)-5,6-dimethyl-7H-pyrrolo<2,3-d>pyrimidin-4(3H)-on 
• 82703-45-5 5,6-Dimethyl-7-(DL-1-phenylethyl)-7H-pyrrolo<2,3-d>pyrimidin-4(3H)-on 
• 55817-74-8 2-Amino-1-cyclohexyl-4,5-dimethyl-3-pyrrolcarbonitril 
• 103026-11-5 2-Amino-1-cyclopentyl-4,5-dimethyl-3-pyrrolcarbonitril 
• 103026-02-4 2-amino-1-(2-furfuryl)-4,5-dimethyl-1H-pyrrole-3-carbonitrile 
• 104915-38-0 2-Amino-4,5-dimethyl-(1-(DL-1-phenylethyl)-3-pyrrolcarbonitril) 

Downstream Products

• 1613479-19-8 C₁₄H₁₁F₂N₃O 

Relevant articles and documents

4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER

The present invention concerns a compound of formula (I), in particular as LIMK and/or ROCK kinases inhibitors. The present invention also concerns these new inhibitors for use for the treatment of a condition selected in the group consisting of: cancers, virion infections, ocular hypertension and glaucoma formation, Neurofibromatosis type 1 and 2, psoriatic lesions, inflammatory diseases and hyperalgesia, central sensitization and chronic pain, reproduction erectile dysfunction, and neuronal diseases. The present description discloses the syntheses and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 32 to 127; examples 1 to 96; families 1 to 8; compounds; biological studies; tables). An exemplary compound is e.g. 4-(5-m ethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-phenyl-3,6-dihydropyridine-1-(2H)-carboxamide (example 1; compound 5).